Newsletter No. 93 -- May 2007
CLINICAL CANCER THERAPY AND PREVENTION RESEARCH (R01) (PA-07-356)(NCI)
Application Receipt/Submission Date(s): Standard dates apply.
The overall aims of this funding opportunity announcement (FOA) are two-fold: (1) to stimulate the development of innovative cancer prevention and therapy clinical trials with or without laboratory correlative studies; and (2) to support innovative correlative laboratory studies retrospectively and prospectively linked to therapeutic/preventive clinical trials.
NIBIB RESEARCH REVISIONS TO PROMOTE CLINICAL RESIDENT RESEARCH EXPERIENCES (Revisions to Currently Active NIBIB R01 and R37 Grants) (PAR-07-363)/ (Supplements to Currently Active NIBIB P01, P41, P50, U01, U54 Grants)(PAR-07-364)
Application Receipt/Submission Date(s): June 13, 2007; October 17, 2007; February 13, 2008; June 13, 2008; October 15, 2008; February 13, 2009; June 15, 2009
The intent of this Funding Opportunity Announcement (FOA) is to provide a 1-2 year period of research experience for physicians in a residency program through revisions to existing NIBIB grant awards. The program targets applicants who have demonstrated the potential for productive research in an area of interest to the candidate and of relevance to the mission of the NIBIB.
URL for PAR-07-363: http://grants.nih.gov/grants/guide/pa-files/PAR-07-363.html
URL for PAR-07-364: http://grants.nih.gov/grants/guide/pa-files/PAR-07-364.html
NOTICE OF AVAILABILITY OF ADMINISTRATIVE SUPPLEMENTS FOR NEUROIMAGING INFORMATICS SOFTWARE ENHANCEMENT FOR IMPROVED INTEROPERABILITY AND DISSEMINATION (NIH Blueprint for Neuroscience Research) (NOT-EB-07-006)
Application: see the Notice
This notice is to announce the availability of supplemental funding, provided by the NIH Blueprint for Neuroscience Research, to modify, document, or otherwise make more adoptable, interoperable, and usable existing neuroimaging informatics tools and resources.
PREAPPLICATION FOR THE MOLECULAR LIBRARIES PROBE PRODUCTION CENTERS NETWORK (MLPCN) [X02] (PAR-07-368)
NIH Roadmap Initiatives
Letter of Intent Receipt Date: May 29, 2007
Application Receipt/Submission Date(s): June 28, 2007
This announcement solicits pre-applications for 3 types of screening and chemical probe generation centers with complementary capabilities and a high degree of flexibility to address a wide range of biological targets and phenotypes in the production phase of the Molecular Libraries Program (MLP). The goal of the MLP is to screen compounds in the Small Molecule Repository in target-based and phenotypic assays to identify and subsequently optimize small molecules as research probes.
AAPM/ASTRO RADIATION ONCOLOGY PHYSICS RESIDENCIES
Application receipt deadline: May 31, 2007
To promote the development of radiation physics residency programs in the United States leading to more graduates and more qualified professionals entering the workforce. The purpose of the Grants is to provide assistance to newly established programs working towards accreditation. Up to $36,000.00 in total funding will be awarded by ASTRO each year, with matching funds awarded by AAPM. Individual program grants will not exceed $12,000.00 each.
CHARLOTTE GEYER FOUNDATION GRANTS
Application Deadline: June 1, 2007
The Charlotte Geyer Foundation provides interim funding to researchers whose R01 and R21 proposals have been reviewed by the National Cancer Institute and were ranked within ten percentage points of the NCI payline. These are 1 year grants for up to $100,000.
RAPID ACCESS TO INTERVENTION DEVELOPMENT (RAID) (NOT-CA-07-018)(NCI)
Receipt dates: February 1, August 1
The NATIONAL CANCER INSTITUTE (NCI) is requesting project proposals in response to the Rapid Access to Intervention Development (RAID) Program. The RAID Program will make available to academic investigators, on a competitive basis, the preclinical development contract resources of NCI's Developmental Therapeutics Program (DTP). RAID is not a grant program.
CIP DCIDE PROGRAM
The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.
CLARIFICATION ON PAGE LIMITS AND BUDGET SUBMISSIONS FOR BIOENGINEERING RESEARCH PARTNERSHIPS (PAR-07-352) (NOT-EB-07-007)
In Section IV.6, under "PHS398 Research Plan Component Sections," the first sentence should state that "Items 2-5 of the PHS398 Research Plan component are limited to 40 pages." There is also information about budget format.
NIH ANNOUNCES CHANGES TO ERA COMMONS, PARTICULARLY THE ELECTRONIC STREAMLINED NON-COMPETING AWARD PROCESS (ESNAP) FUNCTION (NOT-OD-07-064)
Look at this before writing a grant progress report.
NIBIB UPDATE ON POLICIES AND PROCEDURES FOR THE K-SERIES CAREER DEVELOPMENT AWARDS (NOT-EB-07-004)
NIBIB UPDATE ON POLICIES AND PROCEDURES FOR INSTITUTIONAL (T32) and SHORT-TERM INSTITUTIONAL (T35) TRAINING GRANTS (NOT-EB-07-005)
Society of Nuclear Medicine 54th Annual Scientific Meeting - CIP 10th Anniversary Booth #651
June 2 - 6, 2007, Washington, DC
Society for Imaging Informatics in Medicine (SIIM)
June 7-10, 2007, Providence, RI
Frontiers of Biomedical Imaging Science
June 27-29 2007,Nashville, Tennessee
CARS 2007 Computer Assisted Radiology and Surgery -21st International Congress and Exhibition
June 27 - 30, 2007, Bonn, Germany
American Association of Physicists in Medicine (AAPM) - 49th Annual Meeting
July 22-26, 2007, Minneapolis, MN
Molecular Imaging Joint Conference of the Academy of Molecular Imaging and the Society for Molecular Imaging
September 7 - 11, 2007, Providence, Rhode Island
IMAGING IN 2020 V: THERAGNOSTIC IMAGING
September 23-27, 2007, Jackson Hole, Wyoming
The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (email@example.com). Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program,
Division of Cancer Treatment and Diagnosis,
NCI 6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507